What is a pharmacy worth in 2026?

How is a pharmacy valued?

On a multiple of adjusted earnings, plus stock at valuation. That is the method brokers, accountants and lenders use, and the argument is always about the two inputs: what the earnings really are, and what multiple they deserve. The fixtures, fittings and computers are worth little on their own. Almost all of the price is goodwill, which is another way of saying the buyer is paying for a prediction about future profit.

The earnings figure starts from the statutory accounts and is then adjusted. Typical adjustments add back the owner's salary and pension, one-off costs, family members on the payroll above market rates, and personal expenses run through the business. They then deduct what it would cost a buyer to replace the owner's own hours in the dispensary at locum or employed rates. The result is the maintainable profit, expressed as adjusted net profit or as EBITDA, earnings before interest, tax, depreciation and amortisation.

The multiple is a judgement. Brokers weigh NHS item numbers and their trend, the services mix, the lease, the staff, the competition within a mile and the buyer pool at the time. Our guide to buying against starting a pharmacy sets out the factors that raise or lower it. What no one can give you is a fixed number. The multiple is what the market will pay, and in 2026 the market is thin, cautious and full of first-time buyers.

What do the published market reports show?

That prices softened and distress rose after 2022, while buyer demand held up. Christie & Co is the broker that publishes an annual pharmacy price index and buyer survey in its Business Outlook reports, and The Pharmacist has reported the editions cited here. The table sets out the figures reported.

Two things in that table matter for a 2026 valuation. First, the direction of the index. Christie & Co described a "general softening of sale prices" in a year when the base rate reached 5.25% and inflation pushed up wages and overheads. Second, the buyer mix. When nearly half of completed sales go to first-time buyers, prices are set by people borrowing most of the money. Their lenders decide what a pharmacy is worth as much as the buyers do.

We have not been able to cite a published multiple from any broker for this article, and we will not invent one. If a broker or agent quotes you a range, ask for the completed sales it is drawn from, the region, the item numbers and how the profit figure was adjusted. A multiple of unadjusted profit and a multiple of EBITDA after a notional pharmacist salary are different numbers describing the same shop.

What is the NHS contract itself worth?

Most of the goodwill. What a buyer really purchases is the entry on NHS England's pharmaceutical list, because that is what earns the dispensing fees and service income. The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 do not let you sell it on its own. Under regulation 26 a change-of-ownership application succeeds only where the buyer carries on the business at the same premises, provides the same services and does not interrupt them. The GPhC premises registration under the Medicines Act 1968 is applied for afresh by the new owner; see how the GPhC premises application works.

Three features of a listing change its value. A 100-hour condition adds opening hours a buyer must staff, and regulation 67 requires six months' notice to close such premises, against three months for a standard listing. A Pharmacy Access Scheme payment, capped at £17,500 a year and paid to pharmacies more than a mile from the next nearest, or 0.8 miles in the most deprived areas, is income that follows the premises. And a distance selling listing has become scarce: since 23 June 2025 the Regulations no longer allow applications for new distance selling premises, so an existing one can only be bought.

Location inside a controlled locality, where dispensing doctors operate, can also restrict what a buyer may do with the listing later. Our guide to buying a closing pharmacy's contract covers the change-of-ownership and consolidation routes in detail.

What raises the price in 2026?

Provable earnings that do not depend on the seller. Buyers in 2026 are paying for three things above the dispensing baseline. They are rising item numbers, service income with a record behind it, and a business that runs without the owner in the dispensary every day.

Item numbers first. Dispensing volume is the bedrock of the earnings figure because the single activity fee, £1.46 an item since 1 April 2025, is paid on every item. Christie & Co's 2023 review put the average at 8,078 items a month per pharmacy in England. A buyer will compare your figure with that, and with your own trend over three years.

Service income second. Pharmacy First consultations are paid at £17 each since April 2025, and vaccination, contraception and hypertension case-finding all pay per activity. A buyer will want to see the claims in the PMR and the payments on the NHSBSA schedule, month by month. Private services count in the same way. A weight-management, travel or ear-care clinic with two years of consultation records is an asset. One launched in the year of sale is a promise.

Independence from the owner third. If the seller is the only pharmacist, the adjusted profit must carry the cost of replacing them. A pharmacy with an employed pharmacist, an accuracy-checking technician and written procedures loses less on that adjustment and earns a higher multiple.

What do buyers discount?

Anything that makes last year's profit a poor guide to next year's. The list is short and familiar.

The distressed category deserves a word. Christie & Co reported that distressed sales rose from 3% of its transactions in 2022 to 10% by the end of 2023. Jhoots, a chain of more than 100 branches, entered administration at the end of 2025. Buyers now expect some of what comes to market to be forced, and they price accordingly. If your pharmacy is not distressed, the evidence that it is not, in the form of clean accounts and current supplier terms, protects the price.

How does the funding position affect prices?

It sets the ceiling on earnings, and in 2026 it is still uncertain. The 2025/26 settlement, agreed in March 2025, set Community Pharmacy Contractual Framework funding at £3.073bn, with a further £215m for Pharmacy First and related services. The allowed medicines margin rose to £900m and £193m of historic margin over-delivery was written off. At the date of writing, the 2026/27 settlement had not been announced.

The longer picture explains why buyers remain careful. A DHSC written answer on 24 February 2026 put 2015/16 funding at £3,864m in 2025/26 prices, against £3,073m in 2025/26. The independent economic analysis by Frontier Economics and IQVIA, published on 9 October 2024, found 47% of branches were not profitable at EBITDA level in 2023/24. It put the full economic cost of running a pharmacy that year at £409,000 to £573,000. The figures are in the table.

A buyer's lender reads the same figures. Half the network losing money at EBITDA level means half of all pharmacies have no earnings to multiply. That is why the market divides in two. Businesses with services and scale attract several offers. Marginal dispensaries sell for their contract and little else. Our closures analysis shows where the second group is concentrated.

What does a seller keep after tax?

Less than a year ago. Business Asset Disposal Relief taxes qualifying gains at 18% for disposals from 6 April 2026, against 14% in 2025/26 and 10% before 6 April 2025, according to GOV.UK. To qualify, the seller must have owned the business for at least two years, and for company shares must hold at least 5% of the shares and voting rights.

On a £1m gain, the difference between a completion on 5 April 2026 and one on 6 April 2026 is £40,000. The rate rise does not change what a pharmacy is worth, but it changes what a sale is worth to the seller, and it removed one reason to wait. The structure matters too: a share sale and an asset sale are taxed differently, which is why the structure should be settled before the pharmacy is marketed.

Who values a pharmacy for sale?

Three parties, and they rarely agree. Specialist brokers value for marketing purposes and see the completed deals; Christie & Co and Hutchings Consultants both publish pharmacy market commentary and both value businesses for sale. Accountants prepare the adjusted profit figure and advise on the tax position. Lenders instruct their own valuation before lending, and their number governs how much a buyer can borrow.

None of these is a regulated valuation standard for pharmacy goodwill. Treat each figure as evidence, not a verdict, and ask the same questions of all three: which completed sales, how recent, which region, and what adjustments to profit. A seller who has already done the work described above can answer those questions before they are asked. That, in a cautious market, is what moves the multiple.

Key takeaways

FAQs